Morgan Stanley analyst Ravi Shanker said Aurora is leading the charge with the “most sophisticated on-highway Class 8 autonomous solution among peers.”
The company also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet AMD, shifting the timeline from Q4 2025 to Q1 2026.
U.S. stocks plunged Tuesday as President Donald Trump‘s tariffs on key trade partners came into effect, prompting retaliatory measures and intensifying global trade tensions.
Sellers whipped bulls with an undercut of Friday's lows on higher volume disribution. There was no denying which side of the market traders were sitting at.
The S&P 500 trades at elevated multiples. Earnings expectations for this year and next are very high. Enter macro uncertainty surrounding the fiscal/tariff policy of the Trump administration.
The potential impact from President Donald Trump’s tariffs, the continuing uncertainty surrounding the Federal Reserve rate outlook and mixed earnings served as pushbacks in February.
While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials.
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%, down from 50.9% in January.
The Russell 2000 broke below support of the rising channel on the weekly time frame. Meanwhile, the Nasdaq finished the week with a bullish piercing pattern following a successful test of the 200-day MA on higher volume accumulation.
Since September last year, 23 – or thereabouts – has posed difficulty for volatility bulls, and this trend prevailed this week as well.
VIX for now is probably headed lower.
Stocks recovered on Friday, with all three major indexes in the green, as the tech sector bounced back from Thursday's losses with NVIDIA Corp. (NASDAQNVDA) up 1.37% and Tesla, Inc. NASDAQ:TSLANASDAQTSLA)
